Innoviva (HVE) Stock Overview
Operates as a biopharmaceutical company in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
HVE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Innoviva, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$19.60 |
| 52 Week High | US$21.00 |
| 52 Week Low | US$14.20 |
| Beta | 0.38 |
| 1 Month Change | -1.51% |
| 3 Month Change | -1.51% |
| 1 Year Change | 15.98% |
| 3 Year Change | 54.33% |
| 5 Year Change | 81.48% |
| Change since IPO | 98.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| HVE | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 2.1% | 3.0% | 2.8% |
| 1Y | 16.0% | 23.4% | 1.4% |
Return vs Industry: HVE underperformed the German Pharmaceuticals industry which returned 23.4% over the past year.
Return vs Market: HVE exceeded the German Market which returned 1.4% over the past year.
Price Volatility
| HVE volatility | |
|---|---|
| HVE Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: HVE has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: HVE's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 159 | Pavel Raifeld | www.inva.com |
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents.
Innoviva, Inc. Fundamentals Summary
| HVE fundamental statistics | |
|---|---|
| Market cap | €1.44b |
| Earnings (TTM) | €433.58m |
| Revenue (TTM) | €361.67m |
Is HVE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HVE income statement (TTM) | |
|---|---|
| Revenue | US$420.69m |
| Cost of Revenue | US$108.95m |
| Gross Profit | US$311.74m |
| Other Expenses | -US$192.61m |
| Earnings | US$504.34m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.83 |
| Gross Margin | 74.10% |
| Net Profit Margin | 119.88% |
| Debt/Equity Ratio | 23.9% |
How did HVE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/27 08:13 |
| End of Day Share Price | 2026/05/26 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Innoviva, Inc. is covered by 19 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jon Langenfeld | Baird |
| James Birchenough | Barclays |
| Patrick Trucchio | Berenberg |